Investigating RSV infection in adult patients with blood disorders in Tianjin
An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)
This study looks at how often adult patients with blood disorders in Tianjin get RSV infections and how it affects their breathing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tianjin) |
| Trial ID | NCT06490549 on ClinicalTrials.gov |
What this trial studies
This observational study aims to describe the incidence of respiratory syncytial virus (RSV) infection among adult patients who have undergone hematopoietic stem cell transplantation or those diagnosed with hematological malignancies in Tianjin. The study will focus on patients aged 18 and older who exhibit new or worsening respiratory symptoms. By observing these patients, the study seeks to gather valuable epidemiological data on RSV infections in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have received hematopoietic stem cell transplantation or are diagnosed with hematological malignancies and are experiencing respiratory symptoms.
Not a fit: Patients who are unwilling to sign an informed consent form will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of RSV infections in hematological patients, potentially leading to improved prevention and treatment strategies.
How similar studies have performed: While this study focuses on a specific population, similar observational studies have successfully identified the incidence and impact of viral infections in immunocompromised patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1) Aged ≥ 18 years old. 2) Receiving hematopoietic stem cell transplantation; OR being diagnosed with hematological malignancies (including but not limited to leukemia, lymphoma, and multiple myeloma) and receiving chemotherapy. 3) New onset of respiratory symptoms; OR exacerbation of existing chronic respiratory symptoms (such as previously diagnosed chronic runny nose, seasonal allergies, chronic lung disease, etc.). 4) Willing to sign an informed consent form, able to understand and willing to follow the study protocol. Exclusion Criteria: * Unwillingness to sign an informed consent form.
Where this trial is running
Tianjin
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin, China (Recruiting)
Study contacts
- Study coordinator: Erlie Jiang, MD
- Email: jiangerlie@ihcams.ac.cn
- Phone: +86-15122538106
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.